At the core of our delivery technology is a proprietary Nano-in-Micro platform built on inorganic Calcium Phosphate (CaP) nanoparticles. CaP nanoparticles represent a versatile, biomimetic nanocarrier that can be loaded or surface-decorated with biologics.
This non-viral, scalable system is designed for inhalation and other administration routes, offering a safe and effective alternative for advanced drug delivery.
NanoPhoria has identified specific mimetic peptides that capable of restoring key cardiac functions by addressing deficiencies in protein signaling within cardiomyocytes. These peptides act as functional modulators of intracellular pathways involved in calcium handling and contractility, two processes frequently impaired in cardiac disease. By targeting the dysregulated proteins responsible for cardiac dysfunction, these peptides aim to restore physiological cardiomyocyte function and improve cardiac performance. NanoPhoria’s approach enables precise modulation of disease relevant pathways directly within the cells responsible for cardiac contraction.
Oligonucleotides (oligos) are short, synthetic, nucleic acid sequences (DNA or RNA), capable of selectively modulating gene expression and protein production. This modality enables targeted regulation of molecular pathways that drive cardiac dysfunction and pathological remodeling. NanoPhoria is developing oligonucleotide based therapeutics designed to precisely regulate disease driving pathways in cardiomyocytes. By targeting specific genes and transcripts, these therapies aim to reduce (harmful) remodelling, improving contractility, lowering fibrosis and inhibiting cell death.
